Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

State Medicaid programs missed $220 million in uncaptured savings as generic fluoxetine came to market, 2001-05.

Kelton CM, Chang LV, Kreling DH.

Health Aff (Millwood). 2013 Jul;32(7):1204-11. doi: 10.1377/hlthaff.2013.0161.

3.

Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.

Bian B, Gorevski E, Kelton CM, Guo JJ, Martin Boone JE.

J Manag Care Pharm. 2012 Sep;18(7):506-15.

4.

Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.

Kelton CM, Chang LV, Guo JJ, Yu Y, Berry EA, Bian B, Heaton PC.

Appl Health Econ Health Policy. 2014 Apr;12(2):165-77. doi: 10.1007/s40258-014-0083-z.

PMID:
24550087
6.

Utilization, price, and spending trends for antidepressants in the US Medicaid Program.

Chen Y, Kelton CM, Jing Y, Guo JJ, Li X, Patel NC.

Res Social Adm Pharm. 2008 Sep;4(3):244-57. doi: 10.1016/j.sapharm.2007.06.019. Epub 2008 Aug 8.

PMID:
18794035
7.

Medicaid payment for generic drugs: achieving savings and access.

Peters CP.

Issue Brief Natl Health Policy Forum. 2010 Sep 30;(839):1-16.

PMID:
20928958
8.

Brand-name versus generic.

Copeland KR, Boccuzzi SJ.

Health Aff (Millwood). 2007 Jul-Aug;26(4):1198-9; author reply 1199. No abstract available.

9.

Private expenditures on brand name prescription drugs after generic entry.

Balaban DY, Dhalla IA, Law MR, Bell CM.

Appl Health Econ Health Policy. 2013 Oct;11(5):523-9. doi: 10.1007/s40258-013-0052-y.

PMID:
23979876
10.

State generic substitution laws can lower drug outlays under Medicaid.

Shrank WH, Choudhry NK, Agnew-Blais J, Federman AD, Liberman JN, Liu J, Kesselheim AS, Brookhart MA, Fischer MA.

Health Aff (Millwood). 2010 Jul;29(7):1383-90. doi: 10.1377/hlthaff.2009.0424.

11.

Generic drug cost containment in Medicaid: lessons from five state MAC programs.

Abramson RG, Harrington CA, Missmar R, Li SP, Mendelson DN.

Health Care Financ Rev. 2004 Spring;25(3):25-34.

12.

Extensions of intellectual property rights and delayed adoption of generic drugs: effects on medicaid spending.

Kesselheim AS, Fischer MA, Avorn J.

Health Aff (Millwood). 2006 Nov-Dec;25(6):1637-47.

13.

Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.

Patel RA, Walberg MP, Tong E, Tan F, Rummel AE, Woelfel JA, Carr-Lopez SM, Galal SM.

J Manag Care Spec Pharm. 2014 Mar;20(3):283-90.

14.

State Medicaid pharmacy payments and their relation to estimated costs.

Adams EK, Kreling DH, Gondek K.

Health Care Financ Rev. 1994 Spring;15(3):25-42.

15.

Pharmaceuticals and medical devices: cost savings.

Chaps NA.

Issue Brief Health Policy Track Serv. 2009 Jan 5:1-20. No abstract available.

PMID:
19297717
16.

Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.

Chaps NA.

Issue Brief Health Policy Track Serv. 2008 Jan 7:1-27. No abstract available.

PMID:
18345555
17.

Encouraging generic use can yield significant savings.

Zimmerman C.

Find Brief. 2012 Nov;15(8):1-3.

PMID:
23213854
18.

Generic medications for you, but brand-name medications for me.

Keenum AJ, Devoe JE, Chisolm DJ, Wallace LS.

Res Social Adm Pharm. 2012 Nov-Dec;8(6):574-8. doi: 10.1016/j.sapharm.2011.12.004. Epub 2012 Feb 21.

PMID:
22357268
19.

Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

Nunn AS, Fonseca EM, Bastos FI, Gruskin S, Salomon JA.

PLoS Med. 2007 Nov 13;4(11):e305.

20.

Money left on the table: generic drug prices in Canada.

Law MR.

Healthc Policy. 2013 Feb;8(3):17-25.

Items per page

Supplemental Content

Write to the Help Desk